MWA
KPRX icon

Miller Wealth Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

Miller Wealth Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$1.97K – 122
2025
Q4 		$1.97K Buy
+1,000
New +$2.28K ﹤0.01% 108

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Miller Wealth Advisors's KPRX Position: Q1 2026 in Review

Miller Wealth Advisors sold out of Kiora Pharmaceuticals (KPRX) in Q1 2026, closing a stake of 1,000 shares — an estimated $1.97K sold.

Miller Wealth Advisors first reported a position in KPRX in Q4 2025 and held it in 1 quarter. The position peaked at $1.97K in Q4 2025. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • Miller Wealth Advisors reported no remaining Kiora Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Miller Wealth Advisors sold 1,000 Kiora Pharmaceuticals shares in Q1 2026, an estimated $1.97K.
  • Miller Wealth Advisors first reported a position in Kiora Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Miller Wealth Advisors's Kiora Pharmaceuticals position peaked at $1.97K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on Miller Wealth Advisors's 13F filing for Q1 2026, filed 1 May 2026.